The multi-dimensional trap: you can be TRL6 technically and TRL2 clinically

Digital health maturity is not one-dimensional. Many teams reach strong technical performance and assume they are “ready”, but then face resistance from clinical stakeholders. The technology works, yet adoption does not happen.

This is the multi-dimensional trap: being advanced technically while being early clinically.

It happens because tech development has fast feedback loops. Clinical value has slower feedback loops. If you do not manage this intentionally, the roadmap drifts toward building features, while clinical proof remains vague.

A simple way to see the trap is to ask two questions:

1. What clinical claim are we making?
   Not “we improve care”, but a measurable claim tied to a population and a context.
   
   
2. What evidence would change a stakeholder decision?
   Not “people liked it”, but what would convince a clinician lead, a manager, or a partner to adopt.
   
   

If you cannot answer these, you are likely earlier clinically than you think. And when clinical maturity lags, funding and go-to-market suffer. Reviewers and buyers interpret it as risk.

The solution is a maturity matrix. Keep TRL as the headline, but split your plan into at least two tracks: technical proof and clinical proof. Align the next tech build with the next clinical evidence need. Avoid building features that do not strengthen a specific clinical claim.

Worthmed® supports teams by clarifying the clinical claim early through evidence review, then choosing the fastest proof approach: retrospective data analysis when suitable, and focused pilots when real-world workflow proof is required.

‍